[Use of bevacizumab (Avastin) in KID syndrome: case report].

Abstract

KID syndrome is a congenital ectodermal dysplasia characterized by the association of keratitis, hyperkeratotic skin lesions and neurosensorial hearing loss. Ocular involvement occurs in 95% of patients. Although KID syndrome cutaneous manifestations have been studied in-depth, the treatment and prognosis of ophthalmic impairment have not been described in detail. At present, the treatment of the ocular damage caused by the syndrome is symptomatic and there are no studies defining a treatment that could change the disease course. In this case, ophthalmologic findings of a patient with KID syndrome and the use of subconjunctival bevacizumab to treat corneal neovascularization are described. In spite of the absence of improvement in this patient and the few reports of this disease, additional studies with bevacizumab to treat corneal deep neovascularization are suggested.

• Authors: Luiza Caye, Karin Scheid, Melissa Manfroi Dal Pizzol, Roberto Freda
• Journal: Arquivos brasileiros de oftalmologia (Arq Bras Oftalmol) 2010 May-Jun Vol. 73 Issue 3 Pg. 285-90 ISSN: 1678-2925 [Electronic] Brazil
• Vernacular Title: Uso do bevacizumab (Avastin(R)) na síndrome KID: relato de caso.
• PMID: 20730289 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Bevacizumab

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Corneal Neovascularization (drug therapy)
• Deafness
• Humans
• Ichthyosis
• Keratitis
• Male
• Young Adult